GLP-1 agonists, which primarily target extrahepatic mechanisms to ameliorate metabolic disorders, when used in conjunction with resmetirom, focusing on intrahepatic mechanisms, offer a complementary approach in the management of MASH and liver fibrosis
This will give valuable information to clinicians to define their future role and adapt targeted therapeutic strategies to give beneficial long-term outcomes
Your registered dietitian is likely to work with you to help determine what frequency of meals and snacks helps you most with fullness as well as explore your distribution of proteins, fats, and carbohydrates to help with same
This is exactly why controlled trials are needed and why microdosing should be approached with appropriate medical supervision, not self-experimented with based on internet articles alone
8.3 Reduced Appetite and Weight Loss Effects Appetite suppression is both a therapeutic benefit and a physiological effect
Like GLP-1 S, its effect is appetite- and metabolism-driven rather than a direct action on adipose tissue, which keeps it mechanistically separate from AOD-9604 despite both being discussed in fat-loss research contexts